ClinicalTrials.gg
Enrolling by invitationNCT07288840EXCARMAUpdated Dec 17, 2025

Exercise Prescription in Cardiac Rehabilitation Mediated by Autonomic Function

An observational study in Cardiac Rehabilitation, Exercise Therapy and Autonomic Nervous System Imbalance, sponsored by Instituto Politécnico de Leiria. Enrolling by invitation at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Instituto Politécnico de Leiria · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Study summary

Cardiac rehabilitation (CR) is an essential secondary prevention component in the treatment of cardiovascular diseases and one of the most cost- effective clinical interventions. Exercise training (ET) in CR programs (CRP) has unequivocal benefits in the reduction of cardiovascular adverse events, by decreasing the overactivated sympathetic tone. This ET added value can be measured by variables that express autonomic control using indirect (standard) or direct (experimental) methodologies. Direct autonomic assessment (ex. Microneurography) is accurate but unusable in daily practice, whereas standard indirect autonomic assessment using clinical parameters is imprecise, resulting in underprescription to safeguard patient safety, with less benefit to the patients. In this project, we aim to apply Machine Learning models to a set of indirect and direct variables, to make a multivariate correlation analysis and so define a normalization factor for exercise prescription.

Read the detailed description

Cardiac rehabilitation (CR) has proved to be an essential secondary prevention component of the continuum in the treatment of Cardiovascular diseases (CVD), being a Class I recommendation with level of evidence A and B on the European Society of Cardiology (ESC) and American Heart Association and American College of Cardiology (AHA/ACC) Guidelines. CR is also one of the most cost-effective clinical interventions in the treatment of CVD. These diseases, namely coronary artery disease (CAD) and heart failure (HF), are associated with autonomic dysfunction, particularly an overactivation of the autonomic sympathetic system (ASS), leading to coronary vasoconstriction, myocardial remodeling, and increased basal oxygen consumption. The main component of the CR programs (CRP) is Exercise training (ET), one of the central pillars of non- pharmacological treatment in CVD, thus preventing the above- mentioned progression of deleterious effects. The role of ET in CRP has been increasingly emphasized; however, it is still not clear, among the variety of existing training programs, which is the optimal combination and type of exercise (aerobic/anaerobic or both), frequency and duration of the sessions, whose prescription should be customized considering the patient's clinical history and the pre-CRP exam results. This limitation is pointed out as a major drawback in obtaining optimized results on CRP. The absence of a methodology that can more precisely assess and hence better quantify the effect of the prescription, safely optimizing the training plan, is one of the central problems regarding CR, and will be addressed in this research proposal putting the autonomic modulation of CV system in the center of the rational to prescribe ET in CRP. The main objective of this research plan is to draw an objective and individualized protocol to prescribe ET in CRPs based on the Autonomic output.

After careful ponderation, two important but different pathologies with clearly demonstrated ASS overactivation were considered: "non- ischemic HF with reduced ejection fraction" (NIHFrEF) and "CAD without HF" (CADnonHF). The following secondary objectives contribute to the achievement of this central goal, and define the majority of the associated tasks:

  • Evaluation of the basal sympathetic activation pattern in patients with NIHFrEF and CADnonHF (Task2);
  • Definition of a normalization factor regarding sympathetic activation for ET prescription purposes in the context of CRPs (Task3)
  • Definition of an exercise training program for CRPs with prescription guided by the autonomic response (Task 4); In Task 2 the basal activation level of the Autonomic nervous system (ANS) will be characterized for each of the two identified conditions (NIHFrEF and CADnonHF) using a sample of 30 patients for each one to ensure a good approximation of the sampling distribution of the mean using the central limit theorem, and the participants will be enrolled at the CR consultation in Centro Hospitalar de Leiria (CHL) Cardiology department. The CHL CR Unit is accreditated by the European Association of Preventive Cardiology (EAPC) since 2022. Classical indirect measures of ANS which are relatively imprecise, such as heart rate variability (HRV) and derived indexes will be obtained with a 24h Holter and a "long duration EKG", as well as the first minute HR recovery with a Cardiopulmonary Exercise Test (CPET) and also serum catecholamines in blood and urine samples. Besides these indirect measures, a direct recording of the SNS obtained by microneurography (MSNA) will be conducted, being available at the host research institution (ciTechCare). The set of variables (autonomic and its derivatives), together with the metabolic biomarkers, will allow a multivariate correlation analysis followed by the use of the Machine Learning algorithm "Principal Component analysis" (PCA) to reduce the dimensionality of the data set, and so define a normalization factor for exercise prescription purposes, which corresponds to the main goal associated with Task 3. This normalization factor will be key to establish the individual pattern of sympathetic activation, establishing the same starting point for initial prescription of exercise and an unbiased follow up of patient's performance. Regarding Task 4, training plans (aerobic/anaerobic load) will be carried out in conjunction with the levels defined for the classification model (one of the derivable of the previous Task), and will be developed by the candidate along with the Physiatrist of the CRP Team, by setting a combined (aerobic and resistance) and stratified (with various levels of intensity, frequency, stages and duration) training program. This protocol will be evaluated by the due health ethics committees (Task 1), and all legal issues regarding safety and data protection will be respected.

Regarding risks and strategies to mitigate them, the main risk is related to data assessment. In that case other hospitals may be contacted to increase the number of participants. Another risk is related to task dependency. In this case, the experience of the mentors and the integration of this project in a team with expertise in CRP and familiar with artificial intelligence applications in Medicine will be determinant.

02

Conditions studied

  • Cardiac Rehabilitation
  • Exercise Therapy
  • Autonomic Nervous System Imbalance
  • Treatment Outcomes

Keywords

  • Cardiac Rehabilitation
  • Exercise prescription
  • Autonomic funtion
  • microneurography
  • cardiopulmonary exercise testing
03

In context

Lead sponsor

Instituto Politécnico de Leiria is the lead sponsor of 20 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with non-ischemic heart failure with reduced ejection fraction (NIHFrEF) or stable coronary artery disease without heart failure (CADnonHF), consecutively enrolled in the Cardiac Rehabilitation Program at Centro Hospitalar de Leiria, and undergoing comprehensive autonomic and metabolic assessment."

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Coronary artery disease and no heart failure criteria
  • Patients with non ischaemic heart failure and reduced left ventricle

Exclusion criteria

Exclusion Criteria:

  • patients with ongoing acute coronary syndrome
  • patients with ongoing acute decompensated heart failure
  • Severe valvular heart disease that might confound the relationship between exercise and autonomic function.
  • Severe arrhythmias (e.g., sustained ventricular tachycardia, atrial fibrillation with a rapid ventricular rate) that are symptomatic or untreated
  • Severe uncontrolled hypertension (e.g., systolic BP > 180 mmHg or diastolic BP > 110 mmHg)
  • Active infectious diseases or other significant acute medical illnesses (e.g., sepsis, active , acute kidney injury)
  • Pregnancy or lactation (to ensure safety during exercise interventions)
  • Significant cognitive impairment or mental illness (e.g., dementia, schizophrenia) that would impair the ability to follow exercise protocols or understand study instructions
  • nability to comply with study procedures due to any reason (e.g., language barriers, lack of )
  • Chronically states (e.g., with \< 200 cells/µL or on immunosuppressive therapy)
  • Presence of significant comorbidities such as advanced (COPD), kidney disease (e.g., stage 4-5 chronic kidney disease), or uncontrolled diabetes that would make exercise unsafe or confound the study outcomes
  • Critical limb ischemia, or severely symptomatic peripheral artery disease or claudication limiting functional capacity and response to exercise
  • Advanced chronic kidney disease (stage 4 or 5), due to with exercise
  • Severe anemia ( \< 8 g/dL) or other blood disorders that affect exercise capacity
  • Inability to tolerate exercise due to other comorbidities or debility
  • individuals with known autonomic neuropathy (such as poorly controlled diabetes or neurodegenerative disorders)

Specific Exclusion Criteria for Coronary Artery Disease (CAD) without Heart Failure Group:

  • (LVEF) \< 50%
  • Clinical/echocardiographic criteria of heart failure with oreserved ejection fraction.

Specific Exclusion Criteria for Non-Ischemic Heart Failure with Reduced LVEF Group:

  • Ischemic heart disease or previous myocardial infarction
  • LVEF > 40%
  • End-stage heart failure (e.g., patients on a heart transplant list, those with imminent need for mechanical circulatory support like LVAD).
  • Severe fluid overload that cannot be corrected
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with Coronary artery disease without Heart Failure (CADnonHF)

    This group with clearly demonstrated Autonomic Simpathetic System overactivation will have a detailed evaluation of the autonomic nervous system by performing an echocardiogram, 24-hour Holter monitoring, cardiopulmonary exercise test, long-term electrocardiogram, microneurography, and serum and urinary determination of catecholamine levels

  • Patients with non- ischemic Heart Failure with reduced ejection fraction (NIHFrEF)

    This group, that also has clearly demonstrated Autonomic Simpathetic System overactivation, will, in the same way, have a detailed evaluation of the autonomic nervous system by performing an echocardiogram, 24-hour Holter monitoring, cardiopulmonary exercise test, long-term electrocardiogram, microneurography, and serum and urinary determination of catecholamine levels

06

What researchers measure

Primary outcomes

  1. Normalization Factor for Sympathetic Activation Derived from Multimodal Autonomic Assessment

    A composite autonomic normalization factor will be generated using Principal Component Analysis (PCA) applied to multimodal autonomic and metabolic biomarkers (including microneurography-derived MSNA, heart rate variability indices from 24-hour Holter, CPET first-minute heart rate recovery, and serum/urinary catecholamines). This factor will quantify the individual degree of sympathetic activation and will serve as the basis for personalized exercise training prescription (Units of mesaure: unitless)

    Time frame: Baseline (before initiation of cardiac rehabilitation program)

Secondary outcomes

  1. Basal Sympathetic Nervous System Activity (MSNA burst frequency)

    Direct sympathetic activity will be quantified using microneurography (sympathetic nerve activity, MSNA), expressed as bursts/minute (bursts/min), to characterize autonomic dysfunction in NIHFrEF and CADnonHF groups.

    Time frame: Baseline

  2. SDNN (Heart Rate Variability) obtained from 24-hour Holter ECG and long-duration ECG

    Standard deviation of normal-to-normal intervals as an index of overall HRV (Unit of Measure: milliseconds - ms)

    Time frame: Baseline

  3. RMSSD (Heart Rate Variability) obtained from 24-hour Holter ECG and long duration ECG

    Root mean square of successive differences as a measure of parasympathetic activity (Unit of Measure: ms²)

    Time frame: Baseline

  4. LF Power (Heart Rate Variability) Low-frequency spectral power obtained from 24-hour Holter ECG

    LF component of HRV as an index of sympathetic/parasympathetic modulation (Units ms²)

    Time frame: Baseline

  5. LF/HF Ratio (Heart Rate Variability) obtained from 24-hour Holter ECG

    Ratio of low-frequency to high-frequency power reflecting autonomic balance (Unit of Measure: unitless)

    Time frame: Baseline

  6. Plasma epinephrine concentration

    Quantified by blood sample to assess biochemical sympathetic activity. Unit of Measure: pg/mL

    Time frame: Baseline

  7. Plasma norepinephrine concentration

    Quantified by blood sample to assess sympathetic activation (Unit of Measure: pg/mL)

    Time frame: Baseline

  8. Plasma dopamine concentration

    Quantified by blood sample to assess catecholaminergic activity (units of measure pg/mL)

    Time frame: Baseline

  9. Urinary metanephrine

    24-hour urinary excretion as an index of catecholamine metabolism (unit of measure µg/24h)

    Time frame: Baseline

  10. Urinary normetanephrine

    24-hour urinary excretion measurement (unit of measure: µg/24h)

    Time frame: Baseline

  11. Urinary 3-methoxytyramine

    24-hour urinary excretion measurement (unit of measure - µg/24h)

    Time frame: Baseline

  12. CPET First-Minute Heart Rate Recovery

    Difference between peak HR and HR at 1-minute post-exercise during cardiopulmonary exercise test, reflecting parasympathetic reactivation (units of measure: beats per minute)

    Time frame: Baseline

07

Study locations

2 sites
  • ciTechCare - Center for Innovative Care and Health Technology
    Leiria, Leiria District 2414-016, Portugal
  • ICVS - Life and Health Sciences Research Institute, Minho University Medical School
    Braga, Minho 4710-057, Portugal
08

References and documents

Publications

  • Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016 Jan 5;2016(1):CD001800. doi: 10.1002/14651858.CD001800.pub3. PubMed 26730878 ↗
  • Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1269-74. doi: 10.1111/j.1440-1681.2006.04523.x. PubMed 17184514 ↗
  • Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016 Nov 7;37(42):3232-3245. doi: 10.1093/eurheartj/ehw334. Epub 2016 Aug 14. No abstract available. PubMed 27523477 ↗
  • Bento L, Fonseca-Pinto R, Povoa P. Autonomic nervous system monitoring in intensive care as a prognostic tool. Systematic review. Rev Bras Ter Intensiva. 2017 Oct-Dec;29(4):481-489. doi: 10.5935/0103-507X.20170072. PubMed 29340538 ↗
  • Sacramento JF, Ribeiro MJ, Rodrigues T, Olea E, Melo BF, Guarino MP, Fonseca-Pinto R, Ferreira CR, Coelho J, Obeso A, Seica R, Matafome P, Conde SV. Functional abolition of carotid body activity restores insulin action and glucose homeostasis in rats: key roles for visceral adipose tissue and the liver. Diabetologia. 2017 Jan;60(1):158-168. doi: 10.1007/s00125-016-4133-y. Epub 2016 Oct 16. PubMed 27744526 ↗
  • Sandesara PB, Lambert CT, Gordon NF, Fletcher GF, Franklin BA, Wenger NK, Sperling L. Cardiac rehabilitation and risk reduction: time to "rebrand and reinvigorate". J Am Coll Cardiol. 2015 Feb 3;65(4):389-395. doi: 10.1016/j.jacc.2014.10.059. PubMed 25634839 ↗
  • Adler AJ, Martin N, Mariani J, Tajer CD, Owolabi OO, Free C, Serrano NC, Casas JP, Perel P. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Apr 29;4(4):CD011851. doi: 10.1002/14651858.CD011851.pub2. PubMed 28455948 ↗
  • Besnier F, Labrunee M, Pathak A, Pavy-Le Traon A, Gales C, Senard JM, Guiraud T. Exercise training-induced modification in autonomic nervous system: An update for cardiac patients. Ann Phys Rehabil Med. 2017 Jan;60(1):27-35. doi: 10.1016/j.rehab.2016.07.002. Epub 2016 Aug 16. PubMed 27542313 ↗
  • Long L, Anderson L, He J, Gandhi M, Dewhirst A, Bridges C, Taylor R. Exercise-based cardiac rehabilitation for stable angina: systematic review and meta-analysis. Open Heart. 2019 Jun 5;6(1):e000989. doi: 10.1136/openhrt-2018-000989. eCollection 2019. PubMed 31245012 ↗
  • Alter DA, Zagorski B, Marzolini S, Forhan M, Oh PI. On-site programmatic attendance to cardiac rehabilitation and the healthy-adherer effect. Eur J Prev Cardiol. 2015 Oct;22(10):1232-46. doi: 10.1177/2047487314544084. Epub 2014 Jul 30. PubMed 25079239 ↗
  • Andrade N, Alves E, Costa AR, Moura-Ferreira P, Azevedo A, Lunet N. Knowledge about cardiovascular disease in Portugal. Rev Port Cardiol (Engl Ed). 2018 Aug;37(8):669-677. doi: 10.1016/j.repc.2017.10.017. Epub 2018 Jul 25. English, Portuguese. PubMed 30055948 ↗
  • Abreu A, Mendes M, Dores H, Silveira C, Fontes P, Teixeira M, Santa Clara H, Morais J. Mandatory criteria for cardiac rehabilitation programs: 2018 guidelines from the Portuguese Society of Cardiology. Rev Port Cardiol (Engl Ed). 2018 May;37(5):363-373. doi: 10.1016/j.repc.2018.02.006. Epub 2018 Apr 30. English, Portuguese. PubMed 29724635 ↗
  • Atlas Writing Group; ESC Atlas of Cardiology is a compendium of cardiovascular statistics compiled by the European Heart Agency, a department of the European Society of Cardiology.; Developed in collaboration with the national societies of the European Society of Cardiology member countries; Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). Eur Heart J Qual Care Clin Outcomes. 2020 Jan 1;6(1):7-9. doi: 10.1093/ehjqcco/qcz065. No abstract available. PubMed 31957796 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study collects sensitive physiological and clinical information that carries a high risk of re-identification, and current institutional and regulatory constraints do not permit external data sharing.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 17, 2025
StartActual
Jan 2, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 31, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07288840
Lead sponsor
Instituto Politécnico de Leiria
Collaborators
Universidade do Minho - ICVS, Hospital de Santo André, Fundação para a Ciência e a Tecnologia
Responsible party
Alexandre Antunes (Medical Doctor (MD), Cardiologist, Coordinator of the Cardiac Rehabilitation Unit of Hospital Santo André, Instituto Politécnico de Leiria) — Principal investigator
First posted
Dec 17, 2025
Start date
Jan 2, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 17, 2025

Study contacts

Vitor Hugo Eira Pereira, MD, PhD
study director · ICVS - Life and Health Sciences Research Institute, Minho University Medical School
Rui Manuel Fonseca Pinto, MD, PhD
study director · ciTechCare - Center for Innovative Care and Health Technology, Polytechnic University of Leiria
João Carlos Araújo Morais, MD,PhD
study director · ciTechCare - Center for Innovative Care and Health Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion